Mirae Asset Global Investments
NTLA icon

Mirae Asset Global Investments’s Intellia Therapeutics NTLA Stock Holding History

Mirae Asset Global Investments’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$106K Buy
6,249
+87
+1% +$1.22K ﹤0.01% 1230
2026
Q1 		$79K Buy
6,162
+533
+9% +$6.79K ﹤0.01% 1218
2025
Q4 		$50.6K Buy
5,629
+1,479
+36% +$20.4K ﹤0.01% 1393
2025
Q3 		$71.7K Buy
4,150
+149
+4% +$1.83K ﹤0.01% 1286
2025
Q2 		$37.5K Buy
4,001
+537
+16% +$4.41K ﹤0.01% 1301
2025
Q1 		$28K Buy
3,464
+70
+2% +$707 ﹤0.01% 1343
2024
Q4 		$40.6K Sell
3,394
-280
-8% -$4.37K ﹤0.01% 1299
2024
Q3 		$77.2K Buy
3,674
+794
+28% +$18.3K ﹤0.01% 1228
2024
Q2 		$66.8K Sell
2,880
-214,514
-99% -$5.11M ﹤0.01% 1193
2024
Q1 		$7.73M Buy
217,394
+31,536
+17% +$876K 0.02% 743
2023
Q4 		$5.67M Sell
185,858
-100,885
-35% -$2.9M 0.01% 852
2023
Q3 		$9.07M Buy
286,743
+22,633
+9% +$878K 0.02% 650
2023
Q2 		$10.8M Buy
264,110
+46,381
+21% +$1.88M 0.02% 615
2023
Q1 		$8.11M Buy
217,729
+9,458
+5% +$371K 0.02% 717
2022
Q4 		$7.27M Sell
208,271
-3,152
-1% -$150K 0.02% 706
2022
Q3 		$11.8M Buy
211,423
+31,898
+18% +$1.98M 0.03% 520
2022
Q2 		$9.29M Buy
179,525
+103,651
+137% +$5.26M 0.02% 623
2022
Q1 		$5.51M Sell
75,874
-13,707
-15% -$1.16M 0.01% 840
2021
Q4 		$10.6M Sell
89,581
-49,434
-36% -$6.19M 0.02% 668
2021
Q3 		$18.6M Buy
139,015
+26,113
+23% +$3.95M 0.05% 429
2021
Q2 		$18.3M Buy
112,902
+1,604
+1% +$125K 0.05% 422
2021
Q1 		$8.93M Buy
111,298
+50,496
+83% +$3.39M 0.03% 559
2020
Q4 		$3.31M Buy
60,802
+23,700
+64% +$861K 0.01% 765
2020
Q3 		$738K Buy
37,102
+11,795
+47% +$246K ﹤0.01% 1072
2020
Q2 		$532K Buy
25,307
+9,651
+62% +$164K ﹤0.01% 1117
2020
Q1 		$191K Buy
15,656
+1,702
+12% +$22.9K ﹤0.01% 1323
2019
Q4 		$205K Buy
13,954
+3,407
+32% +$47.4K ﹤0.01% 1436
2019
Q3 		$141K Buy
+10,547
New +$168K ﹤0.01% 1396

Other funds holding NTLA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
IEFM
IQ EQ Fund Management Dublin 2, Ireland $1.57B AUM 40.42% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
PA
Pinnacle Associates New York $9.16B AUM 63.5% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
CIC
Canal Insurance Company Greenville, South Carolina $456M AUM 40.11% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return

Mirae Asset Global Investments's NTLA Position: Q2 2026 in Review

Mirae Asset Global Investments increased its Intellia Therapeutics (NTLA) stake by 1.4% in Q2 2026, buying an estimated $1.22K and bringing the position to 6,249 shares worth $106K. The position accounts for ﹤0.01% of the portfolio, ranked #1230.

Mirae Asset Global Investments first reported a position in NTLA in Q3 2019 and has held it in 28 quarters since. The position peaked at $18.6M in Q3 2021. 130 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

  • Mirae Asset Global Investments held 6,249 shares of Intellia Therapeutics worth $106K as of Q2 2026.
  • Mirae Asset Global Investments bought 87 Intellia Therapeutics shares in Q2 2026, an estimated $1.22K.
  • Intellia Therapeutics made up ﹤0.01% of Mirae Asset Global Investments's portfolio in Q2 2026, its #1230 holding.
  • Mirae Asset Global Investments first reported a position in Intellia Therapeutics in Q3 2019 and has held it in 28 quarters since.
  • Mirae Asset Global Investments's Intellia Therapeutics position peaked at $18.6M in Q3 2021.
  • 130 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on Mirae Asset Global Investments's 13F filing for Q2 2026, filed 22 Jul 2026.